Global progress on the elimination of viral hepatitis as a major public health threat: An analysis of WHO Member State responses 2017
Global progress on the elimination of viral hepatitis as a major public health threat: An analysis of WHO Member State responses 2017
复制标题
DOI：
10.1016/j.jhepr.2019.04.002
复制
发表时间：
2019-08-01
期刊：
影响因子：
8.3
通讯作者：
Hutchinson, Sharon
中科院分区：
文献类型：
--
作者：
Smith, Shanley;Harmanci, Hande;Hutchinson, Sharon
背景与目的：2016年，世界卫生大会通过了一项决议，到2030年消除病毒性肝炎这一公共卫生威胁。我们旨在检查全球病毒性肝炎应对措施的现状。方法：2017年，世界卫生组织(WHO)要求所有194个成员国的卫生部完成关于病毒性肝炎政策传播指标的国别概况，涵盖国家计划/资金、公民社会参与、检测指导、获得治疗和战略信息。结果：在194个成员国中，135个(70%)做出了回应，占全球感染乙肝病毒(乙肝)和/或丙型肝炎病毒(丙型肝炎)人口的87%。在作出答复的人中，84人(62%)制定了国家计划，其中49人(58%)有专用资金，62人(46%)参与了民间社会；参与民间社会的人比其他人更有可能有资金支持的计划(52%对23%，p=0.001)。分别有70%和46%的成员国提供了孕妇(乙肝病毒)和注射吸毒者(丙型肝炎病毒)检测指南；59%和38%的成员国报告分别普遍获得了乙肝和丙型肝炎的最佳治疗。结论：大多数乙肝和丙型肝炎患者居住在有国家肝炎战略的国家。与民间社会接触的各国政府在回应方面更为先进。会员国需要为这些国家战略提供资金，并确保受影响的人能够获得肝炎服务，以此作为实现全民健康覆盖努力的一部分。(C)2019年提交人。由Elsevier B.V.代表欧洲肝脏研究协会(EASL)出版。这是CC BY-NC-ND License(http://creativecommons.org/licenses/by-nc-nd/4.0/).下的一篇开放获取文章
Background & Aims: In 2016, the World Health Assembly passed a resolution to eliminate viral hepatitis as a public health threat by 2030. We aimed to examine the status of the global viral hepatitis response.Methods: In 2017, the World Health Organization (WHO) asked the Ministries of Health in all 194 Member States to complete a Country Profile on Viral Hepatitis policy uptake indicators, covering national plans/funding, engagement of civil society, testing guidance, access to treatment, and strategic information.Results: Of 194 Member States, 135 (70%) responded, accounting for 87% of the global population infected with hepatitis B virus (HBV) and/or C virus (HCV). Of those responding, 84 (62%) had developed a national plan, of which, 49 (58%) had dedicated funding, and 62 (46%) had engaged with civil society; those engaged with civil society were more likely to have a funded plan than others (52% vs. 23%, p = 0.001). Guidance on testing pregnant women (for HBV) and people who inject drugs (for HCV) was available in 70% and 46% of Member States, respectively; 59% and 38% of Member States reported universal access to optimal therapies for HBV and HCV, respectively.Conclusions: Most people living with hepatitis B and C reside in a country with a national hepatitis strategy. Governments who engaged with civil society were more advanced in their response. Member States need to finance these national strategies and ensure that those affected have access to hepatitis services as part of efforts to achieve universal health coverage. (c) 2019 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL). This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).